| Name | Title | Contact Details |
|---|
Hunter Pharmacy is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Hunter Pharmacy is based in Austin, TX. You can find more information on Hunter Pharmacy at www.hunterpharmacy.com
Long Island Consultation Center is a Rego Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Orb® Platform automatically syncs health data from your doctor and your apps and wearable devices so you can own it, gives you context so can understand it and helps you improve it so you can transform. For consumers and patients, the Orb® Platform is a cloud-based health management platform that syncs and stores your personal health data from multiple doctor’s offices as well as your apps and wearable devices. On your computer or mobile device, Orb provides you with instant clarity and understanding behind your data while also providing actionable insight and solutions to help improve your health. For providers, the Orb® Platform enables physicians to have more oversight and understanding of their patient populations. Orb connects with both the provider’s current lab networks and/or electronic health record systems as well as the patients` external lab networks to support providers with comprehensive insights into the patient’s lab data. The Orb® Platform also enables providers to quickly identify, contact and support at-risk patient populations. Orb Health has strategically established data connectivity to 120 laboratory networks, 30 EMR platforms, and over 150 wearable devices and apps.
Peerfit connects employers, brokers and insurance carriers to local fitness experiences.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.